8-K Announcements
6Material company update
May 18, 2026·SEC
Material company update
May 7, 2026·SEC
Material company update
Mar 10, 2026·SEC
Cullinan Therapeutics, Inc.(CGEM)Earnings, Financials & Key Ratios
CGEM•NASDAQ
Price updated Jun 19, 2026
AboutCullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.Show more
- Revenue$0
- EBITDA-$241M-22.7%
- Net Income-$220M-31.4%
- EPS (Diluted)-3.72-19.6%
- ROE-44.02%-37.3%
CGEM Key Insights
Cullinan Therapeutics, Inc. (CGEM) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 86 (top 14%)
✗Weaknesses
- ✗Profits declining 33.5% over 5 years
- ✗Weak Piotroski F-Score: 1/9
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when CGEM posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CGEM Price & Volume
Cullinan Therapeutics, Inc. (CGEM) stock price & volume — 10-year historical chart
Loading chart...
CGEM Growth Metrics
Cullinan Therapeutics, Inc. (CGEM) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-23.67%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-21.36%
Return on Capital
10 Years-29.27%
5 Years-23.2%
3 Years-41.42%
Last Year-48.24%
CGEM Recent Earnings
Cullinan Therapeutics, Inc. (CGEM) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.75+10.3%
$0.84
Rev
—
$4M
Q2 2026
Mar 10, 2026Metric
Actual
Est
EPS
$0.77+3.8%
$0.80
Rev
—
$5M
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.77+18.9%
$0.95
Rev
—
$6M
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$1.07-28.9%
$0.83
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.75vs $0.84+10.3% | —vs $4M |
| Q2 2026 | Mar 10, 2026 | $0.77vs $0.80+3.8% | —vs $5M |
| Q4 2025 | Nov 6, 2025 | $0.77vs $0.95+18.9% | —vs $6M |
| Q3 2025 | Aug 7, 2025 | $1.07vs $0.83-28.9% | — |
Based on last 12 quarters of dataView full earnings history →
CGEM Peer Comparison
Cullinan Therapeutics, Inc. (CGEM) competitors in Clinical-Stage Biopharma Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 | |||
 KYMR | 7.38B | 90.43 | -24.51 | -16.72% | -6.12% | -25.02% | 0.05 | |
 RCUS | 2.45B | 24.31 | -7.39 | -4.26% | -156.36% | -68.97% | 0.16 | |
 PRCT | 1.24B | 21.72 | -12.63 | 37.22% | -31.82% | -27.7% | 0.14 | |
 TPST | 5.46M | 1.23 | -0.19 | -7.3% | 1.22 | |||
 AGEN | 124.93M | 3.00 | -882.35 | 10.37% | 52.16% | |||
 NKTR | 1.19B | 60.98 | -6.27 | -43.89% | -284.18% | -87% | 1.66 | |
 ALNY | 37.1B | 278.09 | 119.35 | 65.19% | 13.46% | 98.29% | 1.62 |
Compare CGEM vs Peers
Cullinan Therapeutics, Inc. (CGEM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CGEM Income Statement
Cullinan Therapeutics, Inc. (CGEM) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 18.94M | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | -100% | - | - | - | - |
Cost of Goods Sold | 43K | 70K | 62K | 0 | 0 | 0 | 306K | 0 | 79K |
COGS % of Revenue | - | - | - | - | - | - | - | - | - |
Gross Profit | -43K▲ 0% | -70K▼ 62.8% | -62K▲ 11.4% | 18.94M▲ 30653.2% | 0▼ 100.0% | 0▲ 0% | -306K▲ 0% | 0▲ 100.0% | -79K▲ 0% |
Gross Margin % | - | - | - | 100% | - | - | - | - | - |
Gross Profit Growth % | - | -62.79% | 11.43% | 30653.23% | -100% | - | - | 100% | - |
Operating Expenses | 14.59M | 22.27M | 60.34M | 86.9M | -144.65M | 191.09M | 196.61M | 241.65M | 240.35M |
OpEx % of Revenue | - | - | - | 458.73% | - | - | - | - | - |
Selling, General & Admin | 5M | 5.48M | 17.12M | 29.15M | 40.19M | 42.49M | 53.71M | 54.25M | 52.28M |
SG&A % of Revenue | - | - | - | 153.86% | - | - | - | - | - |
Research & Development | 9.58M | 16.79M | 43.21M | 57.75M | 91.95M | 148.16M | 142.9M | 187.4M | 188.07M |
R&D % of Revenue | - | - | - | 304.87% | - | - | - | - | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | -276.79M | 440K | 0 | 0 | 0 |
Operating Income | -14.59M▲ 0% | -22.27M▼ 52.7% | -60.34M▼ 170.9% | -67.95M▼ 12.6% | 144.65M▲ 312.9% | -191.09M▼ 232.1% | -196.92M▼ 3.1% | -241.65M▼ 22.7% | -240.35M▲ 0% |
Operating Margin % | - | - | - | -358.73% | - | - | - | - | - |
Operating Income Growth % | - | -52.68% | -170.92% | -12.63% | 312.86% | -232.11% | -3.05% | -22.71% | - |
EBITDA | -14.54M | -22.2M | -60.27M | -67.9M | 144.74M | -190.78M | -196.61M | -241.34M | -240.03M |
EBITDA Margin % | - | - | - | -358.45% | - | - | - | - | - |
EBITDA Growth % | - | -52.65% | -171.5% | -12.66% | 313.16% | -231.81% | -3.06% | -22.75% | -15.06% |
D&A (Non-Cash Add-back) | 43K | 70K | 62K | 53K | 93K | 310K | 306K | 311K | 314K |
EBIT | -14.59M | -22.27M | -60.34M | -67.95M | -132.14M | -190.65M | -167.46M | -241.65M | -235.36M |
Net Interest Income | 0 | 620K | 888K | 477K | 6.61M | 21.63M | 29.66M | 22.21M | 19.73M |
Interest Income | 397K | 620K | 888K | 477K | 6.61M | 21.63M | 29.66M | 22.21M | 19.73M |
Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | 397K | 616K | 877K | 469K | 6.67M | 21.87M | 29.46M | 21.77M | 19.31M |
Pretax Income | -14.19M▲ 0% | -21.65M▼ 52.6% | -59.46M▼ 174.6% | -67.48M▼ 13.5% | 151.32M▲ 324.2% | -169.22M▼ 211.8% | -167.46M▲ 1.0% | -219.88M▼ 31.3% | -221.04M▲ 0% |
Pretax Margin % | - | - | - | -356.25% | - | - | - | - | - |
Income Tax | 0 | 0 | 0 | 0 | 42.12M | -14.12M | 117K | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 27.84% | 8.35% | -0.07% | 0% | 0% |
Net Income | -14.19M▲ 0% | -20.04M▼ 41.2% | -51.8M▼ 158.5% | -65.57M▼ 26.6% | 111.21M▲ 269.6% | -153.16M▼ 237.7% | -167.38M▼ 9.3% | -219.88M▼ 31.4% | -221.04M▲ 0% |
Net Margin % | - | - | - | -346.14% | - | - | - | - | - |
Net Income Growth % | - | -41.22% | -158.52% | -26.59% | 269.61% | -237.72% | -9.28% | -31.36% | -23.67% |
Net Income (Continuing) | -14.19M | -21.65M | -59.46M | -67.48M | 109.19M | -155.1M | -167.57M | -219.88M | -221.04M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 1K | 864K | 1.3M | 403K | 0 | 192K | 0 | 0 | 0 |
EPS (Diluted) | -17.74▲ 0% | -19.68▼ 10.9% | -1.19▲ 94.0% | -1.48▼ 24.4% | 2.38▲ 260.8% | -3.69▼ 255.0% | -3.11▲ 15.7% | -3.72▼ 19.6% | -3.73▲ 0% |
EPS Growth % | - | -10.94% | 93.95% | -24.37% | 260.81% | -255.04% | 15.72% | -19.61% | -21.36% |
EPS (Basic) | -17.74 | -19.70 | -1.19 | -1.48 | 2.46 | -3.69 | -3.11 | -3.72 | - |
Diluted Shares Outstanding | 800.04K | 1.02M | 43.52M | 44.29M | 46.64M | 41.55M | 53.77M | 59.05M | 59.2M |
Basic Shares Outstanding | 800K | 1.02M | 43.52M | 44.29M | 45.16M | 41.51M | 53.77M | 59.05M | 59.2M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
CGEM Balance Sheet
Cullinan Therapeutics, Inc. (CGEM) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 34.22M | 100.09M | 212.28M | 296.56M | 474.47M | 480.19M | 414.67M | 386.76M | 361.41M |
Cash & Short-Term Investments | 33.83M | 98.63M | 210.21M | 290.47M | 467.29M | 467.07M | 398.98M | 377.9M | 351.88M |
Cash Only | 33.83M | 63.25M | 168.2M | 59.77M | 156.15M | 98.43M | 83M | 88.33M | 75.08M |
Short-Term Investments | 0 | 35.38M | 42.01M | 230.69M | 311.14M | 368.63M | 315.97M | 289.56M | 276.8M |
Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 3M | 0 | 0 |
Days Sales Outstanding | - | - | - | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 0 | 0 | 7.18M | 13.12M | 12.69M | 8.86M | 9.52M |
Total Non-Current Assets | 421K | 370K | 2.43M | 140.62M | 86.64M | 3.99M | 207.16M | 61.62M | 41.58M |
Property, Plant & Equipment | 233K | 182K | 130K | 77K | 5.3M | 3.53M | 2.35M | 3.05M | 2.78M |
Fixed Asset Turnover | - | - | - | 246.01x | - | - | - | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 140.4M | 80.88M | 0 | 204.44M | 58.27M | 479.07M |
Other Non-Current Assets | 188K | 188K | 2.3M | 147K | 459K | 459K | 366K | 297K | 297K |
Total Assets | 34.64M▲ 0% | 100.46M▲ 190.0% | 214.71M▲ 113.7% | 437.19M▲ 103.6% | 561.12M▲ 28.3% | 484.18M▼ 13.7% | 621.82M▲ 28.4% | 448.37M▼ 27.9% | 402.98M▲ 0% |
Asset Turnover | - | - | - | 0.04x | - | - | - | - | 0.00x |
Asset Growth % | - | 190.01% | 113.72% | 103.62% | 28.35% | -13.71% | 28.43% | -27.89% | -107.88% |
Total Current Liabilities | 1.32M | 2.52M | 14.32M | 11.75M | 22.5M | 28.14M | 30.65M | 37.74M | 35.15M |
Accounts Payable | 296K | 934K | 9.68M | 3.17M | 2.66M | 2.49M | 1.68M | 841K | 2.51M |
Days Payables Outstanding | 2.51K | 4.87K | 56.98K | - | - | - | 2.01K | - | 8.7K |
Short-Term Debt | 0 | 0 | 0 | 0 | 178K | 0 | 0 | 780K | 725K |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 27K | 523K | 1.76M | 3.55M | 1.96M | 7.9M | 1.44M | 36.12M | 31.92M |
Current Ratio | 25.85x | 39.67x | 14.82x | 25.25x | 21.09x | 17.07x | 13.53x | 10.25x | 10.28x |
Quick Ratio | 25.85x | 39.67x | 14.82x | 25.25x | 21.09x | 17.07x | 13.53x | 10.25x | 10.28x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 53.97M | 137.85M | 74K | 65K | 3.59M | 2.15M | 849K | 1.9M | 1.66M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.9M | 1.66M |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 3.59M | 2.15M | 849K | 0 | 125K |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 53.97M | 137.85M | 74K | 65K | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 55.29M | 140.37M | 14.39M | 11.81M | 26.09M | 30.29M | 31.5M | 39.64M | 36.81M |
Total Debt | 0 | 0 | 0 | 0 | 5.19M | 3.59M | 2.15M | 2.68M | 2.38M |
Net Debt | -33.83M | -63.25M | -168.2M | -59.77M | -150.96M | -94.84M | -80.85M | -85.65M | -72.7M |
Debt / Equity | - | - | - | - | 0.01x | 0.01x | 0.00x | 0.01x | 0.01x |
Debt / EBITDA | - | - | - | - | 0.04x | - | - | - | -0.01x |
Net Debt / EBITDA | - | - | - | - | -1.04x | - | - | - | 0.30x |
Interest Coverage | - | - | - | - | - | - | - | - | - |
Total Equity | -20.65M▲ 0% | -39.91M▼ 93.3% | 200.31M▲ 601.9% | 425.37M▲ 112.4% | 535.03M▲ 25.8% | 453.89M▼ 15.2% | 590.33M▲ 30.1% | 408.73M▼ 30.8% | 366.17M▲ 0% |
Equity Growth % | - | -93.26% | 601.93% | 112.35% | 25.78% | -15.16% | 30.06% | -30.76% | -117.52% |
Book Value per Share | -25.81 | -39.21 | 4.60 | 9.60 | 11.47 | 10.92 | 10.98 | 6.92 | 6.19 |
Total Shareholders' Equity | -20.65M | -40.77M | 199.01M | 424.97M | 535.03M | 453.7M | 590.33M | 408.73M | 366.17M |
Common Stock | 1K | 1K | 3K | 4K | 5K | 4K | 6K | 6K | 6K |
Retained Earnings | -20.87M | -41.54M | -93.34M | -158.91M | -47.7M | -200.86M | -368.24M | -588.12M | -637.78M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | -4K | -2K | -838K | -2.6M | -129K | -133K | 1.02M | 127K |
Minority Interest | 1K | 864K | 1.3M | 403K | 0 | 192K | 0 | 0 | 0 |
CGEM Cash Flow Statement
Cullinan Therapeutics, Inc. (CGEM) cash flow — operating, investing & free cash flow history
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -13.55M | -20.9M | -29.77M | -43.43M | -126.66M | -134.28M | -145.3M | -175.75M | -178.64M |
Operating CF Margin % | - | - | - | -229.28% | - | - | - | - | - |
Operating CF Growth % | - | -54.23% | -42.47% | -45.89% | -191.63% | -6.01% | -8.21% | -20.95% | -77.51% |
Net Income | -14.19M | -20.66M | -51.8M | -67.48M | 109.19M | -153.16M | -167.57M | -219.88M | -221.04M |
Depreciation & Amortization | 43K | 70K | 62K | 53K | 93K | 310K | 306K | 311K | 314K |
Stock-Based Compensation | 0 | 0 | 0 | 24.38M | 27.96M | 30.44M | 37.82M | 36.04M | 26.67M |
Deferred Taxes | 0 | 0 | 0 | 3.1M | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 252K | -445K | 15.11M | 67K | -275.08M | -11.52M | -15.47M | -6.31M | 2.84M |
Working Capital Changes | 345K | 135K | 6.85M | -3.54M | 11.18M | -339K | -389K | 14.08M | 12.57M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 225K | 639K | 5.58M | -4.83M | -509K | -167K | -812K | -839K | -892K |
Cash from Investing | -261K | -35.4M | -5.42M | -333.77M | 248.97M | 35.81M | -136.31M | 179.99M | 175.6M |
Capital Expenditures | -261K | -20K | -10K | -589.23K | -1.13M | -208K | 0 | -49K | -11K |
CapEx % of Revenue | - | - | - | 3.11% | - | - | - | - | - |
Acquisitions | 0 | 0 | 1.45M | 923K | 275M | -36.01K | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | -333.77K | 91K | 36.01K | 0 | 0 | -38K |
Cash from Financing | -29K | 85.72M | 140.14M | 268.78M | -25.93M | 40.75M | 266.19M | 1.09M | 1.47M |
Debt Issued (Net) | 0 | 0 | 0 | 0 | -2.2M | 1.82M | 0 | 0 | 0 |
Equity Issued (Net) | -20K | 85.72M | 140.14M | 267.27M | 8.39M | 38.39M | 262.65M | 1.09M | 1.09M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | -9K | 0 | 0 | 1.52M | -32.13M | 538K | 3.54M | 0 | 373K |
Net Change in Cash | -13.84M▲ 0% | 29.42M▲ 312.6% | 104.95M▲ 256.7% | -108.42M▼ 203.3% | 96.38M▲ 188.9% | -57.72M▼ 159.9% | -15.43M▲ 73.3% | 5.33M▲ 134.5% | -1.57M▲ 0% |
Free Cash Flow | -13.81M▲ 0% | -20.92M▼ 51.5% | -29.78M▼ 42.4% | -44.02M▼ 47.8% | -127.8M▼ 190.3% | -134.48M▼ 5.2% | -145.3M▼ 8.0% | -175.8M▼ 21.0% | -178.69M▲ 0% |
FCF Margin % | - | - | - | -232.39% | - | - | - | - | - |
FCF Growth % | - | -51.46% | -42.38% | -47.81% | -190.3% | -5.23% | -8.05% | -20.99% | -18.96% |
FCF per Share | -17.26 | -20.55 | -0.68 | -0.99 | -2.74 | -3.24 | -2.70 | -2.98 | -3.02 |
FCF Conversion (FCF/Net Income) | 0.95x | 1.04x | 0.57x | 0.66x | -1.14x | 0.88x | 0.87x | 0.80x | 0.81x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 37.8M | 0 | 0 | 0 | 0 |
CGEM Key Ratios
Cullinan Therapeutics, Inc. (CGEM) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | -64.59% | -20.96% | 23.16% | -30.98% | -32.06% | -44.02% | -51.45% |
Return on Invested Capital (ROIC) | - | - | -25.63% | 28.94% | -38.57% | -34.01% | -43.54% | -52% |
Gross Margin | - | - | 100% | - | - | - | - | - |
Net Margin | - | - | -346.14% | - | - | - | - | - |
Debt / Equity | - | - | - | 0.01x | 0.01x | 0.00x | 0.01x | 0.01x |
FCF Conversion | 1.04x | 0.57x | 0.66x | -1.14x | 0.88x | 0.87x | 0.80x | 0.81x |
Revenue Growth | - | - | - | -100% | - | - | - | - |
Related:CGEM Dividend History·CGEM Revenue History·CGEM Price History·CGEM P/E History·CGEM Financial Ratios·CGEM Institutional Holders
CGEM SEC Filings & Documents
Cullinan Therapeutics, Inc. (CGEM) SEC filings — annual & quarterly reports (10-K, 10-Q)
CGEM Frequently Asked Questions
Cullinan Therapeutics, Inc. (CGEM) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Cullinan Therapeutics, Inc. (CGEM) grew revenue by 0.0% over the past year. Growth has been modest.
Cullinan Therapeutics, Inc. (CGEM) reported a net loss of $221.0M for fiscal year 2025.
Dividend & Returns
Cullinan Therapeutics, Inc. (CGEM) has a return on equity (ROE) of -44.0%. Negative ROE indicates the company is unprofitable.
Cullinan Therapeutics, Inc. (CGEM) had negative free cash flow of $178.7M in fiscal year 2025, likely due to heavy capital investments.